Cordis Acquires AngioGuard, Inc. for Proprietary Technology Protecting Brain & Heart During Interventional Procedures

Jul 07, 1999, 01:00 ET from Cordis Corporation

    WARREN, N.J., July 7 /PRNewswire/ -- Cordis Corporation today reported it
 acquired AngioGuard, Inc., a privately held company, of Minneapolis, MN, which
 has developed innovative containment technology designed to protect the heart
 and brain from embolic particles potentially dislodged during interventional
 medical procedures.  Terms of the agreement were not disclosed.  Cordis
 Corporation is a Johnson & Johnson (NYSE:   JNJ) company.
     "This acquisition underscores the strength of Cordis' commitment to
 rapidly bring innovative, life-saving technologies to market," said Patrick J.
 O'Neill, Ph.D., Cordis Worldwide Group Vice President, Research & Development
 and New Business Development.  "In combination with Cordis' best-in-class
 carotid stent systems, currently under clinical investigation in the U.S. and
 Europe, AngioGuard's embolic containment technology could enable Cordis to
 offer customers and patients a total solution for the interventional treatment
 of carotid artery disease."
     Jay Yadav, M.D., founder of AngioGuard and Director, Carotid Intervention,
 Department of Cardiology at the Cleveland Clinic Foundation, said, "We are
 pleased to complete this strategic acquisition by Cordis.  We believe this
 merger will provide patients around the world with access to the new and
 potentially life-saving technology."
     During interventional procedures such as carotid stenting and saphenous
 vein graft stenting, emboli (fragments of plaque or debris) that may be
 dislodged can pose significant risk of stroke or acute myocardial infarction.
 AngioGuard has developed proprietary embolic containment technology designed
 to protect the heart and the brain from these particles.  AngioGuard's
 technology incorporates a guidewire with a filter that is placed distal to
 (beyond) the target lesion to capture and retrieve emboli throughout these
 procedures.
     Dr. O'Neill noted: "European approval to market the AngioGuard technology
 for coronary applications has just been received, and we expect approval for
 carotid applications later this year.  We also intend to rapidly initiate U.S.
 clinical trials."
     Cordis Corporation, established in 1959, is the world's largest, most
 comprehensive developer and manufacturer of innovative products for
 circulatory disease and interventional medicine, minimally invasive computer-
 based imaging, and electrophysiology.  In 1996, Cordis merged with Johnson &
 Johnson to form Cordis, a Johnson & Johnson company, with approximately
 3,500 employees worldwide.
     AngioGuard was established in 1997 by Dr. Yadav.
 
 

SOURCE Cordis Corporation
    WARREN, N.J., July 7 /PRNewswire/ -- Cordis Corporation today reported it
 acquired AngioGuard, Inc., a privately held company, of Minneapolis, MN, which
 has developed innovative containment technology designed to protect the heart
 and brain from embolic particles potentially dislodged during interventional
 medical procedures.  Terms of the agreement were not disclosed.  Cordis
 Corporation is a Johnson & Johnson (NYSE:   JNJ) company.
     "This acquisition underscores the strength of Cordis' commitment to
 rapidly bring innovative, life-saving technologies to market," said Patrick J.
 O'Neill, Ph.D., Cordis Worldwide Group Vice President, Research & Development
 and New Business Development.  "In combination with Cordis' best-in-class
 carotid stent systems, currently under clinical investigation in the U.S. and
 Europe, AngioGuard's embolic containment technology could enable Cordis to
 offer customers and patients a total solution for the interventional treatment
 of carotid artery disease."
     Jay Yadav, M.D., founder of AngioGuard and Director, Carotid Intervention,
 Department of Cardiology at the Cleveland Clinic Foundation, said, "We are
 pleased to complete this strategic acquisition by Cordis.  We believe this
 merger will provide patients around the world with access to the new and
 potentially life-saving technology."
     During interventional procedures such as carotid stenting and saphenous
 vein graft stenting, emboli (fragments of plaque or debris) that may be
 dislodged can pose significant risk of stroke or acute myocardial infarction.
 AngioGuard has developed proprietary embolic containment technology designed
 to protect the heart and the brain from these particles.  AngioGuard's
 technology incorporates a guidewire with a filter that is placed distal to
 (beyond) the target lesion to capture and retrieve emboli throughout these
 procedures.
     Dr. O'Neill noted: "European approval to market the AngioGuard technology
 for coronary applications has just been received, and we expect approval for
 carotid applications later this year.  We also intend to rapidly initiate U.S.
 clinical trials."
     Cordis Corporation, established in 1959, is the world's largest, most
 comprehensive developer and manufacturer of innovative products for
 circulatory disease and interventional medicine, minimally invasive computer-
 based imaging, and electrophysiology.  In 1996, Cordis merged with Johnson &
 Johnson to form Cordis, a Johnson & Johnson company, with approximately
 3,500 employees worldwide.
     AngioGuard was established in 1997 by Dr. Yadav.
 
 SOURCE  Cordis Corporation